Clinical Trials | February 13, 2024
Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr
These re-agent and diagnostic test kits come with 99.7% accuracy
These re-agent and diagnostic test kits come with 99.7% accuracy
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Ayush is expanding beyond wellness to therapeutic wellness
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Subscribe To Our Newsletter & Stay Updated
